Hepatitis C: latest news

Hepatitis C resources

Hepatitis C features

Hepatitis C in your own words

Hepatitis C news from aidsmap

More news

Hepatitis C news selected from other sources

  • Cigna's Demonstration of “Real World” Effectiveness for Hepatitis C New Drug

    Cigna is monitoring the health outcomes of customers with hepatitis C who have undergone treatment using a prescription combination with the drug Sovaldi. Cigna found that 91.1% of customers achieved a sustained virologic response (SVR). Customers who have an SVR when tested 12 weeks after the completion of treatment are considered cured.

    17 December 2014 | Insurance News Net
  • Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

    Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”

    12 December 2014 | Chimicles & Tikellis press release
  • Pakistani Blood Transfusions Spreading Hepatitis, HIV: Official

    Lax oversight of blood banks means about a fifth of patients in Pakistan who get regular transfusions have been infected with hepatitis, a top government health official said on Friday. Some also get HIV.

    09 December 2014 | HepatitisCNewDrugs
  • New HCV drugs pass muster in real world

    Clinical trials for some of the new direct-acting agents against hepatitis C (HCV) have yielded some impressive efficacy numbers. But how well do the drugs stack up in the real world?

    11 November 2014 | MedPage Today
  • New pill that can cure hepatitis C approved for patients in Scotland

    Daclatasvir is an oral once-daily pill, used in combination with other medicinal products, to treat adult patients with chronic hepatitis C. The decision makes Scotland the first country in Europe to adopt positive guidance for daclatasvir and means it will be routinely available to eligible patients through the Scottish NHS.

    11 November 2014 | STV
  • Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized

    “Unfortunately, history seems to be repeating itself with BMS, who hasn’t learned from the company’s poor track record responding to the HIV epidemic,” says Rohit Malpani of Doctors Without Borders.

    05 November 2014 | Wall Street Journal
  • Half of people with hepatitis C unaware

    Dr Vivian Hope of Public Health England said: "With around half of those people living with hepatitis C still unaware of their infection, we need to do more to increase diagnosis rates. Ultimately, this will help reduce the current high level of infection we’re still seeing among people who inject drugs."

    05 November 2014 | Public Health England press release
  • IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

    AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

    16 October 2014 | HIVandHepatitis.com
  • Investigating an outbreak of hepatitis C virus among MSM without HIV

    Given the reports about the high-risk practices taking place in London (and likely other cities in high-income countries), it is likely that cases of sexually transmitted HCV are also occurring in some HIV-negative MSM. To investigate this possibility, researchers in London reviewed health-related information collected from HIV-negative patients who sought care at selected clinics in that city.

    01 October 2014 | CATIE
  • Uncovering cases of early HCV infection in HIV-positive men

    While screening the blood samples of patients for HCV antibodies can be useful, a new study suggests that in some cases such antibodies may not appear for several months after HCV infection has occurred. In such cases, acute HCV infection might be missed if antibody tests alone are used for screening - RNA testing should be used to screen HCV infection.

    17 September 2014 | CATIE
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.